Gaucher disease: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by deficient glucocerebrosidase activity due to GBA1 mutations, resulting in glucocerebroside accumulation. Clinical features include hepatosplenomegaly, cytopenia, bone pathology (osteopenia, fractures), and variable neurological involvement (Types 2/3). Diagnosis combines enzyme assays and genetic testing. Treatment focuses on enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) for systemic symptoms, with no effective neuropathic disease modifiers [1][2][9].

Population

Incidence: 1 in 50,000–100,000 globally; up to 1 in 450–1,000 in Ashkenazi Jewish populations [2][6][14]
~6,000 U.S. cases; >90% have Type 1 (non-neuronopathic) [1][6][20]

Burden

Morbidity: Chronic pain, skeletal crises, splenomegaly-related complications, growth delays [1][4][18]
Mortality: Type 2 fatal by age 2–3; Type 3 survival into 20s–30s with treatment [1][2][18]
Economic: Annual ERT costs $200,000–$400,000; lifelong therapy required [8][15]

Therapies

ERT: Intravenous infusions (e.g., imiglucerase) every 2 weeks improve visceral/hematologic parameters [7][9][11]
SRT: Oral agents (e.g., eliglustat) reduce substrate production; approved for adults [3][7][15]
Supportive care: Bisphosphonates, transfusions, splenectomy in refractory cases [4][7][9]

Categories: rare genetic diseases, rare inborn errors of metabolism, rare transplant-related disorders

Research Papers

1,813 drug discovery papers related to Gaucher disease, with 4 first-in-class and 12 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-09 | Extracellular vesicles as minimally invasive biomarkers and therapeutic platforms in rare neurological diseases.

Rare neurological diseases (RND) represent a growing but underrecognized global health burden, particularly in aging populations in whom clinical manifestations appear later in life, resulting in substantial morbidity, reduced quality of life, and increased mortality. Advances in understanding and treating these diseases have been hindered by low prevalence, phenotypic heterogeneity, and complex molecular mechanisms. Importantly, shared genetic and mechanistic links between rare and common neurodegenerative disorders, such as GBA1 (Glucosylceramidase Beta 1) gene variant-associated Gaucher disease (GD) and Parkinson's disease (PD), highlight convergent biological pathways that may be leveraged for biomarker discovery and therapeutic innovation. Notably, individuals heterozygous for pathogenic GBA1 variants, historically considered asymptomatic carriers, are now recognized to have an increased lifetime risk of developing PD and related synucleinopathies. This emerging evidence indicates that even single-allele variants can confer long-term neurological risk, reinforcing the continuum between rare monogenic disorders and more common neurodegenerative diseases. Extracellular Vesicles (EVs) have emerged as a promising, minimally invasive platform for advancing RND research, although translation remains limited by source specificity, vesicle heterogeneity, and incomplete clinical validation. By encapsulating proteins, lipids, and nucleic acids that reflect their cellular origin and disease state, EVs offer unique opportunities for early diagnosis, disease stratification, longitudinal monitoring, and assessment of treatment responses. In this review, we summarize fundamental aspects of EV biology and critically evaluate recent advances in EV-based biomarker discovery for RND, informed by translational insights from more prevalent neurodegenerative conditions. We further discuss the therapeutic potential of EVs, emphasizing their intrinsic biocompatibility, their reported capacity in selected preclinical settings to traverse biological barriers, including the blood-brain barrier, and their versatility as carriers for neuroprotective and gene-modifying cargo. Finally, we address key technical and translational challenges, including isolation, characterization, scalability, and regulatory considerations that currently limit clinical adoption. Collectively, this review highlights emerging opportunities and outlines an integrative translational perspective for EV-based diagnostic and therapeutic strategies into research and clinical paradigms for aging individuals affected by RND.

Open article ↗

2026-07-08 | Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study.

To evaluate the short- and long-term clinical and laboratory outcomes of Enzyme Replacement Therapy (ERT) in Indian patients with Gaucher disease (GD) and to identify factors influencing the therapeutic response. This retrospective, multicentre cohort study included 204 patients with confirmed GD across 13 Indian centres. Eligible participants had received at least one year of ERT and provided both baseline and follow-up data. Patients were stratified by splenectomy status. Longitudinal outcomes assessed over 1-5, 10, and 15 y included hemoglobin levels, platelet counts, liver and spleen volumes, chitotriosidase activity, bone pain, bone mineral density (BMD), and height/weight Z-scores. Subgroup analyses evaluated the impact of age at ERT initiation, GD subtype, genotype, and baseline disease severity. Of the 204 patients, 173 were non-splenectomised and 31 were post-splenectomy; notably, 136 (66.7%) presented with the GD3 phenotype. The median age at symptom onset, diagnosis, and ERT initiation was 1.5 y, 2.6 y, and 4.3 y respectively. The p.L483P allele was the predominant variant in the cohort. Within the first 1-5 y of ERT, non-splenectomised patients demonstrated marked improvements in hematological parameters, organomegaly, biomarker activity, growth metrics, and bone pain. These improvements were sustained through 10-15 y, characterized by stabilized visceral parameters, persistently low biomarker levels, steady growth, and a low incidence of new skeletal complications. Early initiation of ERT was associated with a greater magnitude of hematological response as early as 1 y. ERT facilitates rapid clinical and laboratory improvements within 1-5 y, with benefits sustained over 10-15 y in Indian GD patients. Despite significant diagnostic delays and the advanced stage of disease at presentation common in this population, long-term outcomes remain highly favourable. Early initiation of ERT is critical for optimizing treatment response and preventing irreversible sequelae.

Open article ↗

2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.

Neuronopathic Gaucher disease (nGD) is a lysosomal storage disorder caused by GBA1 mutations, leading to defective acid β-glucosidase (GCase) and accumulation of glycosphingolipid substrates, causing inflammation and neurodegeneration. Patients with nGD manifest severe neurological symptoms, but current animal models fail to fully recapitulate the human condition, posing a major barrier to the development of effective therapies targeting the brain. To bridge this gap, we have developed midbrain-like organoids (MLOs) from human induced pluripotent stem cells of nGD patients with GBA1L444P/P415R and GBA1L444P/RecNcil mutations to model nGD brain pathogenesis. These nGD MLOs exhibited GCase deficiency, resulting in diminished enzymatic function, accumulation of lipid substrates, widespread transcriptomic changes, and impaired dopaminergic neuron differentiation, mirroring nGD pathology. GBA1 mutation correction mediated by CRISPR/Cas9 restored GCase activity, normalized lipid substrate levels, and rescued dopaminergic neuron function, confirming the causal role of GBA1 mutations during early brain development. Using this novel platform, we further evaluated therapeutic strategies, including SapC-DOPS nanovesicles delivering GCase, AAV9-GBA1 gene therapy, and substrate reduction therapy with GZ452, a glucosylceramide synthase inhibitor currently under clinical investigation. These treatments either restored GCase activity, reduced lipid substrate accumulation, improved autophagic and lysosomal abnormalities, or ameliorated dysregulated genes involved in neural development. These patient-specific, 3D neural models offer a transformative, physiologically relevant platform for unraveling disease mechanisms and accelerating the discovery of therapies for patients with nGD.

Open article ↗

2026-07-09 | Extracellular vesicles as minimally invasive biomarkers and therapeutic platforms in rare neurological diseases.

Open article ↗

2026-07-08 | Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study.

Open article ↗

2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

36 orphan drug designations for Gaucher disease, including 5 approved therapies.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
(S)-Quinuclidin-3-yl((R)-5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate	small molecules	EMA	2026-06-19	—	3R Pharma Consulting GmbH
selective glucosylceramide synthase (GCS) inhibitor	small molecules	FDA	2026-04-10	—	Yuhan Corporation
adeno-associated viral vector delivering human GBA1 gene	gene therapies	FDA	2026-01-13	—	Shanghai Vitalgen BioPharma Co., Ltd.
ambroxol	small molecules	FDA	2025-06-10	—	Kalevala Therapeutics Inc.
ambroxol	small molecules	FDA	2025-04-16	—	Agyany Pharma LTD.
Adeno-associated virus 9 vector expressing a functional human codon optimized cDNA encoding glucosylceramidase beta 1	gene therapies	FDA	2024-09-09	—	National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)
Ambroxol hydrochloride	small molecules	EMA	2023-11-08	—	CATS Consultants GmbH
recombinant adeno-associated virus (rAAV)	gene therapies	FDA	2023-10-05	—	Lingyi Biotech Co. Ltd.
Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant	gene therapies	EMA	2021-08-20	—	Spur Therapeutics (Ireland) Limited
Recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta-glucocerebrosidase variant	gene therapies	FDA	2021-08-11	—	Spur Therapeutics Limited
Adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene	gene therapies	EMA	2021-02-19	—	PPD Bulgaria EOOD
AAV9 capsid encapsulating a bicistronic vector encoding for a unique combination of a recombinant human ?-glucocerebrosidase enzyme with the S1S3 variant of the N-acetylglucosamine-Phosphotransferase (S1S3 PTase)	gene therapies	FDA	2020-10-21	—	M6P Therapeutics
Autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta	gene therapies	EMA	2020-08-21	—	PPD Bulgaria EOOD
recombinant adeno-associated virus serotype 9 constitutively expressing codon optimized coding sequence of human GBA1	gene therapies	FDA	2020-01-27	—	Prevail Therapeutics
autologous CD34+ cell enriched hematopoietic stem cells genetically modified ex vivo with a lentiviral vector to contain codon-optimized complementary deoxyribonucleic acid that encodes human beta-glucocerebrosidase	cell therapies	FDA	2019-09-25	—	AVROBIO, Inc.
Modified cholera toxin	proteins	FDA	2017-02-07	—	ERAD Therapeutics, Inc.
Adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene	gene therapies	EMA	2015-03-19	—	The Gauchers Association Limited
(3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate	small molecules	EMA	2014-11-19	—	Sanofi B.V.
venglustat	small molecules	FDA	2014-09-11	—	Genzyme
ambroxol	small molecules	FDA	2011-06-29	—	Zywie LLC
Velaglucerase alfa [Vpriv]	proteins	EMA	2010-06-09	—	Takeda Pharmaceuticals International AG
Taliglucerase alfa	proteins	EMA	2010-03-23	—	Pfizer Europe MA EEIG
Taliglucerase alfa [ELELYSO for injection]	proteins	FDA	2009-09-03	2012-05-01	Pfizer, Inc.
velaglucerase-alfa [VPRIV]	proteins	FDA	2009-06-08	2010-02-26	Takeda Development Center Americas, Inc.
(1R, 2R)-Octanoic acid [2-(2’,3’-dihydro-benzo [1,4] dioxin-6’-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt [Cerdelga]	small molecules	EMA	2007-12-04	2015-01-21	Sanofi B.V.
Afegostat tartrate	small molecules	EMA	2007-10-23	—	[INACTIVE] Amicus Therapeutics UK Limited
isofagomine tartrate	small molecules	FDA	2006-01-10	—	Amicus Therapeutics, Inc.
Alendronate disodium	small molecules	FDA	2001-02-13	—	Richard J. Wenstrup, M.D.
Miglustat [Zavesca]	small molecules	EMA	2000-10-18	—	[INACTIVE] Actelion Registration Limited
miglustat [Zavesca]	small molecules	FDA	1998-05-29	2003-07-31	IC-MedTech Corporation
Retroviral vector, R-GC and GC gene 1750	gene therapies	FDA	1997-05-06	—	Genzyme Corporation
Alglucerase injection	proteins	FDA	1995-07-21	—	Genzyme Corporation
Recombinant retroviral vector - glucocerebrosidase	gene therapies	FDA	1993-11-15	—	Genetic Therapy, Inc.
PEG-glucocerebrosidase	proteins	FDA	1992-12-09	—	National Institute of Mental Health, NIH
Imiglucerase [Cerezyme]	proteins	FDA	1991-11-05	1994-05-23	Genzyme Corporation
L-cycloserine	small molecules	FDA	1989-08-01	—	Lev, Meir M.D.

Gaucher disease

Gaucher disease

Gaucher disease

Overview

Population

Burden

Therapies

Categories: rare genetic diseases, rare inborn errors of metabolism, rare transplant-related disorders

Research Papers

2026-07-09 | Extracellular vesicles as minimally invasive biomarkers and therapeutic platforms in rare neurological diseases.

2026-07-08 | Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study.

2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.

2026-07-09 | Extracellular vesicles as minimally invasive biomarkers and therapeutic platforms in rare neurological diseases.

2026-07-08 | Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study.

2026-06-23 | Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies.

Drug Discovery Landscape

Updated: Aug 3, 2026